In a SEC filing dated 2018-02-21, Neogenomics Inc released their full Feburary 2019 Investor presentation. Investment Highlights Leading publicly-traded, comprehensive, pure-play oncology testing company in the U.S. Substantial Oncology/Genetics Market tailwinds Significant near-term growth drivers Market share gains driven by customer satisfaction Rapidly growing Pharma Services business Track record […]